{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:26:24Z","timestamp":1783124784605,"version":"3.54.6"},"reference-count":25,"publisher":"Georg Thieme Verlag KG","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Endocrinol Diabetes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>ObjectivesFibroblast growth factor 21 is a metabolic regulator involved in\n                    glucose and lipid homeostasis. However, its relationship with excessive\n                    intrapancreatic fat deposition in type 2 diabetes mellitus remains unclear. We\n                    aimed to evaluate the association between serum fibroblast growth factor 21\n                    levels and excessive intrapancreatic fat deposition in patients with type 2\n                    diabetes mellitus.<\/jats:p>\n                  <jats:p>MethodsThis prospective cross-sectional study included 101 participants\n                    who had previously undergone abdominal computed tomography. Group 1 consisted of\n                    patients with type 2 diabetes mellitus and excessive intrapancreatic fat\n                    deposition (n=31), Group 2 consisted of patients with type 2 diabetes\n                    mellitus without excessive intrapancreatic fat deposition (n=40), and\n                    Group 3 consisted of individuals without type 2 diabetes mellitus or excessive\n                    intrapancreatic fat deposition (n=30). Excessive intrapancreatic fat\n                    deposition was assessed on computed tomography by a blinded radiologist.\n                    Correlation, multivariable logistic regression, and receiver operating\n                    characteristic analyses were performed.<\/jats:p>\n                  <jats:p>ResultsFibroblast growth factor 21 levels were higher in Group 1 than in\n                    Groups 2 and 3 (82.32 pg\/mL vs. 48.36 pg\/mL vs 48.36 pg\/mL, respectively;\n                        p&lt;0.001). Serum fibroblast growth factor 21 levels were inversely\n                    correlated with the pancreas-to-spleen ratio in the overall cohort\n                    (\u03c1=\u2212\u20090.527, p&lt;0.001) and in the type 2 diabetes mellitus\n                    subgroup (\u03c1=\u2212\u20090.510, p&lt;0.001). In multivariate analysis, higher\n                    serum fibroblast growth factor 21 levels were independently associated with\n                    excessive intrapancreatic fat deposition both in the subgroup with diabetes\n                    (odds ratio: 1.03, 95% confidence interval: 1.01\u20131.05; p=0.004) and in\n                    the overall study population (odds ratio: 1.03, 95% confidence interval:\n                    1.01\u20131.05; p=0.003). Receiver operating characteristic analysis showed an\n                    area under the curve (AUC) of 0.796 for fibroblast growth factor 21 in\n                    predicting excessive intrapancreatic fat deposition. A fibroblast growth factor\n                    21 cutoff value of&gt;62.15 pg\/mL yielded a sensitivity of 83.87% and a\n                    specificity of 67.14%.<\/jats:p>\n                  <jats:p>ConclusionsSerum fibroblast growth factor 21 levels were increased in\n                    patients with type 2 diabetes mellitus and excessive intrapancreatic fat\n                    deposition and were independently associated with excessive intrapancreatic fat\n                    deposition. Circulating fibroblast growth factor 21 may reflect pancreatic fat\n                    accumulation in the setting of metabolic dysfunction.<\/jats:p>","DOI":"10.1055\/a-2899-6872","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:10:43Z","timestamp":1783123843000},"source":"Crossref","is-referenced-by-count":0,"title":["Association of Fibroblast Growth Factor 21 with Excessive\n                    Intrapancreatic Fat Deposition in Type 2 Diabetes Mellitus"],"prefix":"10.1055","author":[{"given":"Beste","family":"Ozturk","sequence":"additional","affiliation":[{"name":"Ministry of Health Ankara Bilkent City\n                    Hospital, Ankara, Turkey","place":["\u00c7ankaya"],"department":["Department of Internal Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4977-9919","authenticated-orcid":false,"given":"Mustafa","family":"Comoglu","sequence":"additional","affiliation":[{"name":"Ministry of Health Ankara Bilkent City\n                    Hospital, Ankara, Turkey","place":["\u00c7ankaya"],"department":["Department of Internal Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oguzhan","family":"Zengin","sequence":"additional","affiliation":[{"name":"Ministry of Health Ankara Bilkent City\n                    Hospital, Ankara, Turkey","place":["\u00c7ankaya"],"department":["Department of Internal Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esma","family":"Andac Uzdogan","sequence":"additional","affiliation":[{"name":"Ministry of Health Ankara Bilkent City\n                    Hospital, Ankara, Turkey","place":["\u00c7ankaya"],"department":["Department of Biochemistry"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emre","family":"Buyukkaplan","sequence":"additional","affiliation":[{"name":"Ministry of Health Ankara Bilkent City\n                    Hospital, Ankara, Turkey","place":["\u00c7ankaya"],"department":["Department of Diagnostic Radiology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emra A","family":"Kalkan","sequence":"additional","affiliation":[{"name":"Ministry of Health Ankara Bilkent City\n                    Hospital, Ankara, Turkey","place":["\u00c7ankaya"],"department":["Department of Internal Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ihsan","family":"Ates","sequence":"additional","affiliation":[{"name":"Ministry of Health Ankara Bilkent City\n                    Hospital, Turkey","place":["Ankara"],"department":["Department of Internal Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.3389\/fimmu.2020.01582","article-title":"The effects of type 2 diabetes mellitus on organ metabolism and the immune\n                    system","volume":"11","author":"G Daryabor","year":"2020","journal-title":"Front Immunol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1624472","DOI":"10.3389\/fendo.2025.1624472","article-title":"A review of type 2 diabetes mellitus and cognitive impairment","volume":"16","author":"W Kan","year":"2025","journal-title":"Front Endocrinol"},{"issue":"04","key":"ref3","doi-asserted-by":"crossref","first-page":"101501","DOI":"10.1016\/j.aohep.2024.101501","article-title":"The Janus of a disease: Diabetes and metabolic dysfunction-associated fatty\n                    liver disease","volume":"29","author":"F Barrera","year":"2024","journal-title":"Ann Hepatol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"154961","DOI":"10.1016\/j.metabol.2021.154961","article-title":"The clustering of cardiovascular, renal, adipo-metabolic eye and liver disease\n                    with type 2 diabetes","volume":"128","author":"M Thomas","year":"2022","journal-title":"Metabolism"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molmet.2019.05.001","article-title":"What role do fat cells play in pancreatic tissue?","volume":"25","author":"F Gerst","year":"2019","journal-title":"Mol Metab"},{"issue":"06","key":"ref6","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1007\/s00125-025-06392-9","article-title":"Intrapancreatic adipocytes and beta cell dedifferentiation in human type 2\n                    diabetes","volume":"68","author":"N Zhang","year":"2025","journal-title":"Diabetologia"},{"issue":"03","key":"ref7","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41575-021-00551-0","article-title":"Intra-pancreatic fat deposition: Bringing hidden fat to the fore","volume":"19","author":"M S Petrov","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"09","key":"ref8","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1089\/dia.2023.0157","article-title":"A systematic review of exocrine pancreatic insufficiency prevalence and\n                    treatment in type 1 and type 2 diabetes","volume":"25","author":"D M Lewis","year":"2023","journal-title":"Diabetes Technol Ther"},{"issue":"01","key":"ref9","first-page":"7764963","article-title":"The prevalence and characteristics of exocrine pancreatic insufficiency in\n                    patients with type 2 diabetes: A systematic review and meta-analysis","volume":"2022","author":"J Zhang","year":"2022","journal-title":"Int J Endocrinol"},{"issue":"01","key":"ref10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-physiol-021115-105339","article-title":"Understanding the physiology of FGF21","volume":"78","author":"F M Fisher","year":"2016","journal-title":"Ann Rev Physiol"},{"issue":"03","key":"ref11","doi-asserted-by":"crossref","first-page":"101064","DOI":"10.1016\/j.gendis.2023.06.033","article-title":"Fibroblast growth factor 21: An emerging pleiotropic regulator of lipid\n                    metabolism and the metabolic network","volume":"11","author":"S Li","year":"2024","journal-title":"Genes Dis"},{"issue":"10","key":"ref12","doi-asserted-by":"crossref","first-page":"4147","DOI":"10.1111\/dom.15787","article-title":"Research advances in understanding crosstalk between organs and pancreatic\n                    \u03b2-cell dysfunction","volume":"26","author":"P Huang","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"02","key":"ref13","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/dom.16089","article-title":"The role of the glucagon-FGF21 axis in improving beta cell function during\n                    glucose intolerance and SGLT2 inhibition","volume":"27","author":"M Moreno-Lopez","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.2337\/dc24-S002","article-title":"2. Diagnosis and classification of diabetes: Standards of care in\n                    diabetes\u20142024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"issue":"01","key":"ref15","doi-asserted-by":"crossref","first-page":"e70185","DOI":"10.1002\/ueg2.70185","article-title":"International multidisciplinary consensus report on definitions, diagnostic\n                    criteria, and management of fatty pancreas: A joint statement endorsed by EPC,\n                    APA, EASD, EASL, ESGAR, ESGE, ESP, ESPCG, ESPEN, ESPGHAN, IAP, JPS, KPBA, LAPSG,\n                    and UEG","volume":"14","author":"M Vujasinovic","year":"2026","journal-title":"United Eur Gastroenterol J"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"e220493","DOI":"10.20945\/2359-4292-2022-0493","article-title":"Use of FGF21 analogs for the treatment of metabolic disorders: A systematic\n                    review and meta-analysis","volume":"68","author":"M P Carbonetti","year":"2023","journal-title":"Arch Endocrinol Metab"},{"issue":"06","key":"ref17","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1210\/clinem\/dgac729","article-title":"Circulating FGF21 concentration, fasting plasma glucose, and the risk of type 2\n                    diabetes: results from the PREVEND study","volume":"108","author":"A Post","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"09","key":"ref18","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41419-019-1893-6","article-title":"Fibroblast growth factor 21 Ameliorates diabetes-induced endothelial dysfunction\n                    in mouse aorta via activation of the CaMKK2\/AMPK\u03b1 signaling pathway","volume":"10","author":"L Ying","year":"2019","journal-title":"Cell Death Dis"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"103202","DOI":"10.1016\/j.ebiom.2020.103202","article-title":"A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and\n                    non-alcoholic steatohepatitis","volume":"63","author":"Q Pan","year":"2021","journal-title":"EBioMedicine"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"116306","DOI":"10.1016\/j.bcp.2024.116306","article-title":"Potential of FGF21 in type 2 diabetes mellitus treatment based on untargeted\n                    metabolomics","volume":"225","author":"S Li","year":"2024","journal-title":"Biochem Pharmacol"},{"issue":"01","key":"ref21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jcp.29879","article-title":"Relationship between FGF21 and drug or nondrug therapy of type 2 diabetes\n                    mellitus","volume":"236","author":"C Guo","year":"2021","journal-title":"J Cell Physiol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.canlet.2020.11.026","article-title":"FGF21 in obesity and cancer: New insights","volume":"499","author":"W Lu","year":"2021","journal-title":"Cancer Lett"},{"issue":"11","key":"ref23","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"R Loomba","year":"2023","journal-title":"N Engl J Med"},{"issue":"07","key":"ref24","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: A randomized, double-blind,\n                    placebo-controlled, phase 2a trial","volume":"27","author":"S A Harrison","year":"2021","journal-title":"Nat Med"},{"issue":"07","key":"ref25","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S2468-1253(23)00064-X","article-title":"Fatty change of the pancreas: the Pandora\u2019s box of pancreatology","volume":"8","author":"M S Petrov","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Experimental and Clinical Endocrinology &amp; Diabetes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2899-6872.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:10:50Z","timestamp":1783123850000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2899-6872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":25,"URL":"https:\/\/doi.org\/10.1055\/a-2899-6872","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0947-7349","1439-3646"],"issn-type":[{"value":"0947-7349","type":"print"},{"value":"1439-3646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]}}}